share_log

Retail Investors in Jiangsu Bioperfectus Technologies Co., Ltd. (SHSE:688399) Are Its Biggest Bettors, and Their Bets Paid off as Stock Gained 11% Last Week

Retail Investors in Jiangsu Bioperfectus Technologies Co., Ltd. (SHSE:688399) Are Its Biggest Bettors, and Their Bets Paid off as Stock Gained 11% Last Week

江苏Bioperfectus科技股份有限公司(上海证券交易所代码:688399)的散户投资者是其最大的博彩玩家,上周股票上涨了11%,他们的赌注得到了回报
Simply Wall St ·  04/30 02:20

Key Insights

关键见解

  • Significant control over Jiangsu Bioperfectus Technologies by retail investors implies that the general public has more power to influence management and governance-related decisions
  • The top 16 shareholders own 50% of the company
  • Insider ownership in Jiangsu Bioperfectus Technologies is 14%
  • 散户投资者对江苏Bioperfectus Technologies的严格控制意味着公众拥有更大的影响管理和治理相关决策的权力
  • 前16名股东拥有公司50%的股份
  • 江苏Bioperfectus Technologies的内部所有权为14%

Every investor in Jiangsu Bioperfectus Technologies Co., Ltd. (SHSE:688399) should be aware of the most powerful shareholder groups. With 49% stake, retail investors possess the maximum shares in the company. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).

江苏Bioperfectus科技股份有限公司(上海证券交易所股票代码:688399)的每位投资者都应该知道最强大的股东群体。散户投资者持有该公司49%的股份,是公司的最大股份。也就是说,如果股票上涨,该集团将受益最大(如果股价下跌,则损失最大)。

Clearly, retail investors benefitted the most after the company's market cap rose by CN¥417m last week.

显然,在上周该公司的市值上涨了4.17亿元人民币之后,散户投资者受益最大。

In the chart below, we zoom in on the different ownership groups of Jiangsu Bioperfectus Technologies.

在下图中,我们放大了江苏Bioperfectus Technologies的不同所有权群体。

ownership-breakdown
SHSE:688399 Ownership Breakdown April 30th 2024
SHSE: 688399 所有权明细 2024 年 4 月 30 日

What Does The Institutional Ownership Tell Us About Jiangsu Bioperfectus Technologies?

关于江苏Bioperfectus Technologies,机构所有权告诉我们什么?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

机构在向自己的投资者报告时通常会根据基准来衡量自己,因此,一旦股票被纳入主要指数,他们通常会对股票更加热情。我们预计大多数公司都会有一些机构在册,尤其是在它们正在成长的情况下。

Since institutions own only a small portion of Jiangsu Bioperfectus Technologies, many may not have spent much time considering the stock. But it's clear that some have; and they liked it enough to buy in. If the company is growing earnings, that may indicate that it is just beginning to catch the attention of these deep-pocketed investors. When multiple institutional investors want to buy shares, we often see a rising share price. The past revenue trajectory (shown below) can be an indication of future growth, but there are no guarantees.

由于机构仅拥有江苏Bioperfectus Technologies的一小部分股份,因此许多机构可能没有花太多时间考虑这只股票。但很明显,有些人有;他们很喜欢它,足以买进。如果该公司正在增加收益,那可能表明它才刚刚开始引起这些财力雄厚的投资者的注意。当多个机构投资者想要购买股票时,我们经常会看到股价上涨。过去的收入轨迹(如下所示)可以预示未来的增长,但无法保证。

earnings-and-revenue-growth
SHSE:688399 Earnings and Revenue Growth April 30th 2024
SHSE: 688399 2024 年 4 月 30 日收益和收入增长

Hedge funds don't have many shares in Jiangsu Bioperfectus Technologies. Looking at our data, we can see that the largest shareholder is Shaoxing Runkang Biomedical Equity Investment Partnership Enterprise (Limited Partnership) with 27% of shares outstanding. With 8.4% and 2.5% of the shares outstanding respectively, Guoqiang Wang and Zhonghua Liu are the second and third largest shareholders. Note that the second and third-largest shareholders are also Chief Executive Officer and Member of the Board of Directors, respectively, meaning that the company's top shareholders are insiders.

对冲基金在江苏Bioperfectus Technologies的股份不多。从我们的数据来看,我们可以看到最大股东是绍兴润康生物医药股权投资合伙企业(有限合伙),已发行股份的27%。王国强和刘忠华分别拥有8.4%和2.5%的已发行股份,是第二和第三大股东。请注意,第二和第三大股东也分别是首席执行官和董事会成员,这意味着公司的最大股东是内部人士。

Looking at the shareholder registry, we can see that 50% of the ownership is controlled by the top 16 shareholders, meaning that no single shareholder has a majority interest in the ownership.

从股东登记册来看,我们可以看到50%的所有权由前16名股东控制,这意味着没有一个股东拥有所有权的多数股东。

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. As far as we can tell there isn't analyst coverage of the company, so it is probably flying under the radar.

虽然研究公司的机构所有权可以为您的研究增加价值,但研究分析师的建议以更深入地了解股票的预期表现也是一种好做法。据我们所知,没有分析师对该公司进行报道,因此它可能处于雷达之下。

Insider Ownership Of Jiangsu Bioperfectus Technologies

江苏 Bioperfectus 科技的内部所有权

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

不同国家对内部人士的定义可能略有不同,但董事会成员总是计算在内。管理层最终向董事会负责。但是,经理成为执行董事会成员的情况并不少见,特别是如果他们是创始人或首席执行官。

I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.

我通常认为内部所有权是一件好事。但是,在某些情况下,这使其他股东更难追究董事会对决策的责任。

Our information suggests that insiders maintain a significant holding in Jiangsu Bioperfectus Technologies Co., Ltd.. It has a market capitalization of just CN¥4.3b, and insiders have CN¥610m worth of shares in their own names. It is great to see insiders so invested in the business. It might be worth checking if those insiders have been buying recently.

我们的信息表明,内部人士持有江苏Bioperfectus科技有限公司的大量股份。它的市值仅为43亿元人民币,内部人士以自己的名义持有价值6.1亿元人民币的股票。很高兴看到内部人士对这项业务进行如此投资。可能值得检查一下这些内部人士最近是否在买入。

General Public Ownership

一般公有制

The general public-- including retail investors -- own 49% stake in the company, and hence can't easily be ignored. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

包括散户投资者在内的公众拥有该公司49%的股份,因此不容忽视。尽管这种所有权规模可能不足以影响对他们有利的政策决定,但它们仍然可以对公司政策产生集体影响。

Private Company Ownership

私人公司所有权

It seems that Private Companies own 33%, of the Jiangsu Bioperfectus Technologies stock. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.

看来私营公司拥有江苏Bioperfectus Technologies股票的33%。私营公司可能是关联方。有时,内部人士通过控股私营公司而对上市公司拥有权益,而不是以个人身份拥有权益。尽管很难得出任何宽泛的结论,但值得注意的是,这是一个需要进一步研究的领域。

Next Steps:

后续步骤:

While it is well worth considering the different groups that own a company, there are other factors that are even more important.

虽然值得考虑拥有公司的不同群体,但还有其他更为重要的因素。

I always like to check for a history of revenue growth. You can too, by accessing this free chart of historic revenue and earnings in this detailed graph.

我一直喜欢查看收入增长的历史。您也可以,通过访问此详细图表中的这张免费的历史收入和收益图表。

Of course this may not be the best stock to buy. Therefore, you may wish to see our free collection of interesting prospects boasting favorable financials.

当然,这可能不是最值得买入的股票。因此,您可能希望看到我们免费收集的具有良好财务状况的有趣潜在客户。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注意:本文中的数字是使用过去十二个月的数据计算得出的,这些数据是指截至财务报表日期当月最后一天的12个月期间。这可能与全年年度报告数据不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发